The vaccine could be created as a ready-to-use product, rather than needing to be personalised
News
Book your tickets and join the PM Society for the 40th PM Awards on 20 March 2026
The PM Awards celebrate creativity in pharmaceutical marketing and healthcare communications
Sun Pharma’s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma
More than 71% of patients treated with Unloxcyt achieved disease control
Venner Shipley announces opening of new Bristol office
The firm already has a number of offices across the UK and Europe
AAX Biotech and Vascurie announce new neuro-oncology collaboration
The collaboration will help to advance a pipeline of antibody candidates
Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
Company prepares marketing submission after treatment shows strong efficacy
Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
Decision introduces zolbetuximab for eligible patients in NHS Scotland
Ipsen announces new data on Dysport in neurological disease
Dysport reduces muscle contractions by blocking the transmission of nerve impulses
PMGroup Worldwide Ltd welcomes MAD World Summit
Acquisition expands PMGroup’s commitment to transforming workplace health and organisational resilience
Argenx receives review from FDA for VYVGART in seronegative gMG
Regulator accepts supplemental application supported by positive phase 3 data
Nuclera extends Series C funding to advance antibody engineering
Investment to accelerate development of full‑format antibody capabilities on eProtein Discovery system
Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
New manufacturing technologies aim to accelerate next-generation cell therapy development
Fabentech secures French approval for Ricimed antidote
Authorisation marks major step in European preparedness against ricin
Oxford Drug Design reports major in vivo milestone for novel cancer therapy
Data shows potential route to overcoming resistance in aggressive colorectal tumours
Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
Partnership will analyse m6A RNA modifications in patient samples to support development of STC‑15
